FDA labels and CMS rules checked Oct 23, 2026
What Is GLP-1 Used For? Every FDA-Approved Use, by Drug
GLP-1 drugs are FDA-approved for type 2 diabetes and weight management, plus four specific conditions: heart risk, MASH liver disease, kidney disease in diabetes and sleep apnea. PCOS and prediabetes are not approved uses.
- 8 approved uses
- MASH: accelerated approval
- PCOS, prediabetes: not approved
We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure
Chia Health
Our #1 pick for GLP-1 weight loss online
- One monthly price: clinician, medication and free shipping included
- Semaglutide or tirzepatide, as a weekly injection or a daily tablet
- No insurance needed; HSA/FSA and Klarna accepted
Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure
$212.89 first month, then $349/mo
6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.
01 The list
GLP-1 Approved Uses, Drug by Drug
Each GLP-1 brand has its own label, and the label decides what the drug is approved for. That is why the same molecule can be "for diabetes" as Ozempic and "for weight loss" as Wegovy. Every use below is paired with diet and physical activity on the label.
| Use | Drugs | FDA approval | Who | Medicare route |
|---|---|---|---|---|
| Type 2 diabetes (blood sugar) Approved Ozempic Dec 5, 2017; Mounjaro May 13, 2022 · Adults; Victoza, Trulicity and Mounjaro also 10+ | Ozempic, Mounjaro, Trulicity, Victoza, Ozempic tablets | Ozempic Dec 5, 2017; Mounjaro May 13, 2022 | Adults; Victoza, Trulicity and Mounjaro also 10+ | Part D plan |
| Weight management, adults Approved Wegovy Jun 4, 2021; Zepbound Nov 8, 2023; Foundayo Apr 1, 2026 · BMI 30+, or 27+ with a weight-related condition | Wegovy pen and pill, Zepbound, Foundayo, Saxenda | Wegovy Jun 4, 2021; Zepbound Nov 8, 2023; Foundayo Apr 1, 2026 | BMI 30+, or 27+ with a weight-related condition | GLP-1 Bridge, $50 |
| Weight management, ages 12 to 17 Approved Saxenda Dec 4, 2020; Wegovy Dec 23, 2022 · Teens with obesity | Wegovy pen, Saxenda | Saxenda Dec 4, 2020; Wegovy Dec 23, 2022 | Teens with obesity | Not applicable |
| Heart attack, stroke and CV death risk, no diabetes needed Approved Mar 8, 2024 (pen); Dec 22, 2025 (pill) · Adults with heart disease and obesity or overweight | Wegovy pen and pill | Mar 8, 2024 (pen); Dec 22, 2025 (pill) | Adults with heart disease and obesity or overweight | Part D plan |
| Heart risk in type 2 diabetes Approved Ozempic Jan 16, 2020; Mounjaro Aug 27, 2026 · Adults with type 2 diabetes | Ozempic, Victoza, Trulicity, Rybelsus, Mounjaro | Ozempic Jan 16, 2020; Mounjaro Aug 27, 2026 | Adults with type 2 diabetes | Part D plan |
| Kidney disease with type 2 diabetes Approved Jan 28, 2025 · Adults with type 2 diabetes and CKD | Ozempic | Jan 28, 2025 | Adults with type 2 diabetes and CKD | Part D plan |
| MASH (fatty liver) with F2 to F3 fibrosis Accelerated approval Aug 15, 2025 · Adults, no cirrhosis | Wegovy pen | Aug 15, 2025 | Adults, no cirrhosis | Part D plan only |
| Moderate to severe obstructive sleep apnea Approved Dec 20, 2024 · Adults with obesity | Zepbound | Dec 20, 2024 | Adults with obesity | Part D plan only |
| PCOS (now also called PMOS) Not FDA-approved for this use No approval · Off-label; weight indication may apply | None | No approval | Off-label; weight indication may apply | Not a covered use |
| Prediabetes or diabetes prevention Not FDA-approved for this use No approval · Weight indication may apply | None | No approval | Weight indication may apply | Bridge: BMI 27+ with prediabetes |
Sources: section 1 of each prescribing information (Wegovy 06/2026, Ozempic 05/2026, Zepbound 08/2026, Saxenda 02/2026); approval dates from Drugs@FDA. Medicare route per CMS Bridge guidance. Rybelsus is listed by the FDA as to be discontinued.
02 By condition
GLP-1 Uses: One Page per Condition
Wegovy for heart risk
SELECT trial: 20% fewer heart attacks, strokes and CV deaths in 17,604 adults without diabetes.
Accelerated approval Aug 15, 2025Wegovy for MASH
Fatty liver with F2 to F3 scarring: 63% vs 34% saw steatohepatitis resolve at week 72.
Approved Jan 28, 2025Ozempic for kidney disease
FLOW trial: 24% lower risk of kidney failure, major eGFR loss or CV death in type 2 diabetes with CKD.
Approved Dec 20, 2024Zepbound for sleep apnea
Breathing events fell by 25 to 29 an hour in 52-week trials; the first drug approved for OSA.
Ages 12+GLP-1 for teens
Wegovy and Saxenda are approved from age 12. Zepbound and Foundayo are adults only.
Not FDA-approved for this useGLP-1 for PCOS
No GLP-1 is approved for PCOS. What small trials and the 2023 international guideline say.
Not FDA-approved for this useGLP-1 for prediabetes
No drug is approved to prevent diabetes; the weight indication and the Medicare Bridge can still apply.
03 Coverage
Why the Approved Use Changes What You Pay
Insurers decide coverage by diagnosis. A plan that excludes "weight loss drugs" can still pay for the same drug prescribed for a medical condition on its label. Expect prior authorization in both cases.
Commercial plans
Weight-loss coverage is an employer choice. Heart-risk, sleep apnea and MASH requests are often reviewed under separate criteria; UnitedHealthcare, for example, covers Wegovy for heart risk and MASH with prior authorization on plans that exclude weight loss. See UnitedHealthcare, Aetna, Blue Cross.
Medicare
Weight management alone: the GLP-1 Bridge, $50/mo from Jul 1, 2026 to Dec 31, 2027. Diabetes, sleep apnea, MASH or a prescription to cut heart risk: your Part D plan and its copay. Details: Medicare GLP-1 Bridge.
Off-label use
Legal for a doctor to prescribe, but plans rarely pay for it. For PCOS or prediabetes, coverage usually depends on whether you meet the weight indication by BMI. More: GLP-1 cost with insurance.
04 Cost
Self-Pay Prices Do Not Depend on the Use
Manufacturer cash prices are the same whatever the prescription is for. As of October 2026:
$199 first 2 fills
NovoCare
LillyDirect, by dose
NovoCare
Sources: NovoCare, Eli Lilly, read Oct 2026. Every option side by side: GLP-1 cost.
Ro's insurance concierge checks coverage for Wegovy, Ozempic and Zepbound and files prior authorizations. Membership $74 to $149 a month, medication billed separately (Oct 2026).
Have Ro check your coverage05 FAQ
GLP-1 Uses FAQ
What is GLP-1 used for?
What is Wegovy approved for?
Is Ozempic FDA-approved for weight loss?
Can a doctor prescribe a GLP-1 for an unapproved use?
Does the indication change insurance coverage?
Which GLP-1s are approved for teenagers?
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
Last updated Oct 29, 2026 · indications from FDA labels · Medicare rules from CMS · prices from NovoCare and LillyDirect, Oct 2026.
References
- Wegovy (semaglutide) Prescribing Information, revised 06/2026, section 1, checked 2026-10-23, Novo Nordisk / FDA, 2026
- Ozempic (semaglutide) Prescribing Information, revised 05/2026, section 1, checked 2026-10-23, Novo Nordisk / FDA, 2026
- Zepbound (tirzepatide) Prescribing Information, revised 08/2026, sections 1 and 8.4, checked 2026-10-23, Eli Lilly / FDA, 2026
- Saxenda (liraglutide) Prescribing Information, revised 02/2026, section 1, checked 2026-10-23, Novo Nordisk / FDA, 2026
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight, Mar 8, 2024, U.S. Food and Drug Administration, 2024
- FDA Approves First Medication for Obstructive Sleep Apnea, Dec 20, 2024, U.S. Food and Drug Administration, 2024
- Drugs@FDA: approval history for NDA 215256 (Wegovy), 209637 (Ozempic), 217806 (Zepbound), 206321 (Saxenda), U.S. Food and Drug Administration, 2026
- Medicare GLP-1 Bridge: information for Part D plans, checked 2026-10-23, Centers for Medicare & Medicaid Services, 2026
- Weight-loss drugs coverage, checked 2026-10-23, Medicare.gov, 2026